Federal regulators have agreed to review a Swiss pharmaceutical company's applications for two cheaper generic versions of ...

For years, GLP-1 drugs like Wegovy and Zepbound have transformed the discussion around obesity — but left millions locked out by high price tags, including Medicare recipients. That changes this week.

Medicare will soon cover costs of weight-loss drugs. Here’s what you can expect to pay. - Popular Novo Nordisk and Eli Lilly ...

Contrave and Zepbound are two U.S. Food and Drug Administration (FDA)-approved medications for weight loss when combined with diet and exercise. But each medication works in different ways in the body ...

Novo Nordisk'sNVO oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday. Novo Nordisk stock jumped on the news. In comparison, Eli Lilly'sLLY weight-loss shot ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Sign up here to get The Boston Globe’s latest food stories delivered to your inbox once a week. In April, I went public with a secret: I’d begun taking the weight ...

As around 2 in 5 U.S. adults meet the criteria for obesity, GLP-1 drugs have exploded in popularity as a weight loss aid. A recent meta-analysis found that one of these medications may promote weight ...

Serena Williams' weight loss is, in part, due to her use of GLP1s.

Meaghan is an editor and writer who also has experience practicing holistic medicine as an acupuncturist and herbalist. She's passionate about helping individuals live full, healthy and happy lives at ...

Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty ImagesThis article originally appeared onHealthline A ...